CDK4 and breast carcinoma: In contrast to previous studies using the CDK4/6 inhibitor Abemaciclib in a breast cancer model as well as in CT-26 tumor-bearing mice (24), we did not observe a selective decrease in the frequency of Tregs within CD4+ T cells.